Latest News & Features
Big Pharma
With Brexit looming, questions are being asked about the future regulatory relationship between the EU and the UK, with life sciences companies wondering how they will be affected. LSIPR reports. 4 June 2018
Americas
As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports. 4 June 2018
Americas
As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area. 4 June 2018
Americas
Pharma companies with an interest in protecting clinical trial data in Mexico should follow international developments rather than looking closer to home, say Anna Arroyo and Fernando Granados of Uhthoff Gómez Vega & Uhthoff. 3 June 2018
Americas
Mexico’s guidelines on the advertising of alcoholic beverages should be reviewed by the courts because of concerns about their lawfulness, as Daniel Sanchez and Victor Ramirez of Olivares report. 3 June 2018
Americas
Brazil’s IP office now expedites patent applications directed to the Zika virus and other neglected diseases, as Ana Paula Jardim and Andréa Granthon of Luiz Leonardos report. 2 June 2018
Europe
The UK Intellectual Property Office’s official opinion service on infringement and validity can be a useful tool for parties seeking to file oppositions at the European Patent Office, as Anthony Carlick of Dennemeyer & Associates reports. 2 June 2018
Americas
The US International Trade Commission announced yesterday that it will investigate certain blood cholesterol testing systems and strips after receiving a complaint from Polymer Technology System. 1 June 2018
Africa
Médecins Sans Frontières has welcomed the South African government’s release of a new IP policy, calling it an effort to take off a “patent blindfold”. 1 June 2018
Americas
It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione. 1 June 2018